Bristol-Myers Squibb Co

BMY is in a Stage 2 advancing phase after clearing a multi-month range, but price is currently extended above rising EMAs and recent resistance with extreme overbought readings. Execution should be deferred—stalking for pullbacks into the rising 9/20 EMAs or the prior resistance-turned-support zone to align with the bullish medium-term bias.

• ↑Growth portfolio sales rose 17% YoY to $12.3B in Q2 2025.
• ↑Disciplined R&D cuts cycle times by 30% to boost pipeline.
• ↓Legacy portfolio faces 15%–17% revenue step-down from generics.